Journal of the American Society of Hypertension
Volume 1, Issue 6 , Pages 400-406 , November 2007

Increased hematocrit before blood pressure in men who develop hypertension over 20 years

  • Arne Strand, MD

      Affiliations

    • Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    • Corresponding Author InformationCorresponding author: Arne Strand, MD, Department of Cardiology, Ullevaal University Hospital, Kirkeveien 166, N-0407 Oslo, Norway. Tel: + 47 22 11 91 99; fax: + 47 22 11 91 81.
    • ,
  • Helga Gudmundsdottir, MD

      Affiliations

    • Department of Nephrology, Ullevaal University Hospital, Oslo, Norway
    • ,
  • Aud Høieggen, MD, PhD

      Affiliations

    • Department of Nephrology, Ullevaal University Hospital, Oslo, Norway
    • ,
  • Eigil Fossum, MD, PhD

      Affiliations

    • Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    • ,
  • Reidar Bjørnerheim, MD, PhD

      Affiliations

    • Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    • ,
  • Ingrid Os, MD, PhD

      Affiliations

    • Department of Nephrology, Ullevaal University Hospital, Oslo, Norway
    • ,
  • Sverre E. Kjeldsen, MD, PhD

      Affiliations

    • Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    • Department of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA

Received 25 May 2007 ,Accepted 9 July 2007.

References 

  1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561–1566
  2. Levy D, Salomon M, D’Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786–1793
  3. Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, et al. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Circulation. 2006;113:67–73
  4. Weber KT, Brilla CG, Cleland JG, Cohn JN, Hansson L, Heagerty AM, et al. Cardioreparation and the concept of modulating cardiovascular structure and function. Blood Press. 1993;2:6–21
  5. Glasser SP. Hypertension, hypertrophy, hormones, and the heart. Am Heart J. 1998;135:S16–S20
  6. Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis. 2003;166:345–349
  7. Strand AH, Gudmundsdottir H, Os I, Smith G, Westheim AS, Bjornerheim R, et al. Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. J Hypertens. 2006;24:905–913
  8. Strand AH, Gudmundsdottir H, Fossum E, Os I, Bjornerheim R, Kjeldsen SE. Arterial plasma vasopressin and aldosterone predict left ventricular mass in men who develop hypertension over 20 years. J Clin Hypertens (Greenwich). 2007;9:365–371
  9. Facchini FS, Carantoni M, Jeppesen J, Reaven GM. Hematocrit and hemoglobin are independently related to insulin resistance and compensatory hyperinsulinemia in healthy, non-obese men and women. Metabolism. 1998;47:831–835
  10. Smith WC, Lowe GD, Lee AJ, Tunstall-Pedoe H. Rheological determinants of blood pressure in a Scottish adult population. J Hypertens. 1992;10:467–472
  11. Fowkes FG, Lowe GD, Rumley A, Lennie SE, Smith FB, Donnan PT. The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur Heart J. 1993;14:597–601
  12. Sandhagen B, Frithz G, Waern U, Ronquist G. Increased whole blood viscosity combined with decreased erythrocyte fluidity in untreated patients with essential hypertension. J Intern Med. 1990;228:623–626
  13. Hoieggen A, Fossum E, Nesbitt SD, Palmieri V, Kjeldsen SE. Blood viscosity, plasma adrenaline and fasting insulin in hypertensive patients with left ventricular hypertrophy (ICARUS, a LIFE Substudy. Insulin CARotids US Scandinavica). Blood Press. 2000;9:83–90
  14. Devereux RB, Drayer JI, Chien S, Pickering TG, Letcher RL, DeYoung JL, et al. Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol. 1984;54:592–595
  15. Os I, Kjeldsen SE, Westheim A, Aakesson I, Norman N, Enger E, et al. Decreased central dopaminergic activity in essential hypertension. J Hypertens. 1987;5:191–197
  16. Kjeldsen SE, Mundal R, Sandvik L, Erikssen G, Thaulow E, Erikssen J. Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men. J Hypertens. 2001;19:1343–1348
  17. Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–1187
  18. Os I, Kjeldsen SE, Skjoto J, Westheim A, Lande K, Aakesson I, et al. Increased plasma vasopressin in low renin essential hypertension. Hypertension. 1986;8:506–513
  19. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol. 1992;20:1180–1186
  20. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995;25:417–423
  21. Dahlof B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, et al. Characteristics of 9,194 patients with left ventricular hypertrophy: the LIFE Study (Losartan Intervention for Endpoint Reduction in Hypertension). Hypertension. 1998;32:989–997
  22. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M–mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–1083
  23. Wachtell K, Smith G, Gerdts E, Dahlof B, Nieminen MS, Papademetriou V, et al. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE Study) (Losartan Intervention for Endpoint). Am J Cardiol. 2000;85:466–472
  24. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Association of carotid atherosclerosis and left ventricular hypertrophy. J Am Coll Cardiol. 1995;25:83–90
  25. Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease: the Framingham Heart Study: a 34-year follow-up. Am Heart J. 1994;127:674–682
  26. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, Reaven GM. Insulin resistance and cigarette smoking. Lancet. 1992;339:1128–1130
  27. Hoieggen A, Fossum E, Moan A, Enger E, Kjeldsen SE. Whole-blood viscosity and the insulin-resistance syndrome. J Hypertens. 1998;16:203–210
  28. Pratt MC, Lewis–Barned NJ, Walker RJ, Bailey RR, Shand BI, Livesey J. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. Br J Clin Pharmacol. 1992;34:363–365
  29. Johnson RJ, Rodriguez–Iturbe B, Kang DH, Feig DI, Herrera-Acosta J. A unifying pathway for essential hypertension. Am J Hypertens. 2005;18:431–440
  30. Lavoie JL, Sigmund CD. Mini-review: overview of the renin-angiotensin system: an endocrine and paracrine system. Endocrinology. 2003;144:2179–2183
  31. Marathias KP, Agroyannis B, Mavromoustakos T, Matsoukas J, Vlahakos DV. Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem. 2004;4:483–486
  32. Cohn JN. Relationship of plasma volume changes to resistance and capacitance vessel effects of sympathomimetic amines and angiotensin in man. Clin Sci. 1966;30:267–278
  33. Leren P, Askevold EM, Foss OP, Froili A, Grymyr D, Helgeland A, et al. The Oslo Study (Cardiovascular disease in middle-aged and young Oslo men). Acta Med Scand Suppl. 1975;588:1–38

 Supported by the Norwegian Health Association and the Norwegian Foundation for Health and Rehabilitation.

 Conflict of interest: none.

PII: S1933-1711(07)00159-3

doi: 10.1016/j.jash.2007.07.002

Journal of the American Society of Hypertension
Volume 1, Issue 6 , Pages 400-406 , November 2007

Article Tools

* Image Usage & Resolution